TY - BOOK AU - Blass,Benjamin E. TI - Basic principles of drug discovery and development SN - 9780124115088 (paperback) AV - RM301.25 .B59 2015 U1 - 615.19 23 PY - 2015///] CY - Amsterdam, Boston PB - Elsevier/AP, Academic Press is an imprint of Elsevier KW - Drug development KW - Drugs KW - Design KW - Drug Discovery KW - Drug Evaluation KW - fast KW - Chimie pharmaceutique KW - ram KW - Chimie bioorganique KW - Pharmacologie moléculaire KW - Médicaments KW - Conception N1 - pharmacy bookfair2016; Includes biblographical references and indexes; Front Cover; Basic Principles of Drug Discovery and Development; Copyright; Dedication; Contents; Foreword; Chapter 1 -- Drug Discovery and Development: An Overview of Modern Methods and Principles; DRUG DISCOVERY AND DEVELOPMENT FROM 20,000FEET (FIGURE 1.7); TARGET SELECTION: THE FIRST STEP FORWARD; HIT IDENTIFICATION: FINDING A STARTING POINT; IDENTIFY A CLINICAL CANDIDATE: JUGGLING THE PROPERTIES; QUESTIONS; References; Chapter 2 -- The Drug Discovery Process: From Ancient Times to the Present Day; THE AGE OF BOTANICALS: PREINDUSTRIAL DRUG DISCOVERY PAUL EHRLICH: THE FATHER OF MODERN DRUG DISCOVERY10MILESTONES IN DRUG DISCOVERY; THE RISE OF BIOLOGICS AND MACROMOLECULAR THERAPEUTICS; SOCIETAL AND GOVERNMENTAL IMPACTS; REGULATORY MILESTONES; FUTURE DEVELOPMENTS IN DRUG DISCOVERY; QUESTIONS; References; Chapter 3 -- Classical Targets in Drug Discovery; PROTEIN STRUCTURE; ENZYMES; INHIBITION OF ENZYMES; G-PROTEIN-COUPLED RECEPTORS (GPCRS); ION CHANNELS; MEMBRANE TRANSPORT PROTEINS (TRANSPORTERS); EMERGING TARGETS; QUESTIONS; References; Chapter 4 -- In vitro Screening Systems; THE LANGUAGE OF SCREENING: BASIC TERMS; STREPTAVIDIN AND BIOTIN BIOCHEMICAL VERSUS CELLULAR ASSAYSASSAY SYSTEMS AND METHODS OF DETECTION; RADIOLIGAND ASSAY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA); FLUORESCENCE-BASED ASSAY SYSTEMS; REPORTER GENE ASSAYS; KINETIC FLUORESCENT MEASUREMENT SYSTEMS; LABEL-FREE ASSAY SYSTEMS; ELECTROPHYSIOLOGICAL PATCH CLAMP; GENERAL CONSIDERATION FOR ALL SCREENING METHODS; QUESTIONS; References; Chapter 5 -- Medicinal Chemistry; STRUCTURE-ACTIVITY RELATIONSHIPS AND STRUCTURE-PROPERTY RELATIONSHIPS; THE ROLE OF CHIRALITY; PUSH AND PULL IN STRUCTURE-ACTIVITY RELATIONSHIPS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS THE PHARMACOPHOREDEVELOPING AN SAR DATA SET; THE STRUCTURE-ACTIVITY RELATIONSHIP CYCLE; BIOISOSTERISM; STRUCTURE-ACTIVITY RELATIONSHIP, SELECTIVITY AND PHYSICOCHEMICAL PROPERTIES; "DRUGLIKE" GUIDELINES; QUESTIONS; References; Chapter 6 -- In vitro ADME and In vivo Pharmacokinetics; ABSORPTION; DISTRIBUTION; ELIMINATION PATHWAYS; IN VITRO ADME SCREENING METHODS; IN VIVO PHARMACOKINETICS; SPECIES SELECTION; QUESTIONS; References; Chapter 7 -- Animal Models of Disease States; SOURCES OF ANIMAL MODELS; VALIDITY OF ANIMAL MODELS; SPECIES SELECTION; NUMBER OF ANIMALS EXEMPLARY ANIMAL MODELS BY DISEASE CATEGORYANIMAL MODELS OF INFECTIOUS DISEASE; ANIMAL MODELS OF ONCOLOGY; QUESTIONS; References; Chapter 8 -- Safety and Toxicology; SOURCES OF TOXICITY; ACUTE VERSUS CHRONIC TOXICITY; CYTOTOXICITY; CARCINOGENICITY, GENOTOXICITY, AND MUTAGENICITY; DRUG-DRUG INTERACTIONS; CARDIOVASCULAR SAFETY AND TOXICOLOGY STUDIES; CENTRAL NERVOUS SYSTEM SAFETY AND TOXICOLOGY STUDIES; IMMUNE SYSTEM MEDIATED SAFETY ISSUES; TERATOGENICITY; IN VIVO TOXICITY AND SAFETY STUDIES; QUESTIONS; References; Chapter 9 -- Basics of Clinical Trials; BEFORE THE CLINIC; DRUG SUPPLY UR - http://repository.fue.edu.eg/xmlui/handle/123456789/1807 ER -